marked the 40th annual J.P. Morgan Healthcare conference, one of the biggest industry events of the year. The conference, held virtually this year, featured hundreds of companies across the sector discussing their accomplishments in 2021 and what they expect for 2022. Of course, dominating every discussion was the ongoing Covid-19 pandemic, and several companies directly involved in developing Covid-19 treatments, vaccines and tests.
Moderna CEO Stephane Bancel highlighted the growth of his company’s vaccine business, which shipped 807 million doses in 2021 and took in over $17 billion in revenue. The company’s next big thing is its work on a vaccine that can tackle multiple respiratory viruses at once. It’s currently doing clinical trials for a Covid/flu combination and plans to expand that over the next few years to include RSV and even a common cold. “We think this is in reach,” Bancel said.In 2021, Regeneron delivered 2.
Pfizer announced at the conference that it’s preparing to manufacture 120 million doses of its Covid antiviral treatment, Paxlovid. That’s more than it currently has pre-orders for. Bourla said this is because the company anticipates high levels of orders from governments for stockpiling purposes.